Format

Send to

Choose Destination
See comment in PubMed Commons below
Autoimmun Rev. 2009 Jun;8(7):591-4. doi: 10.1016/j.autrev.2009.02.008. Epub 2009 Feb 11.

Long term treatment of rheumatoid arthritis with rituximab.

Author information

1
Rheumatology Dept, IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy. caporali@smatteo.pv.it

Abstract

B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.

PMID:
19393205
DOI:
10.1016/j.autrev.2009.02.008
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center